Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition ...

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia Provided by GlobeNewswire Jul 8, 2025, 5:00:00 AM ...

“Dosing the first patient in the DAHLIA trial marks a pivotal moment for Recursion as we combine the power of our AI-enabled platform with cutting-edge science to pioneer a new class of targeted ...

Chris Gibson, Ph.D., Co-founder and CEO of Recursion said, “REC-1245 is a prime example of using an expansive AI-enabled platform for drug discovery. After exploring many predicted biological ...

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia Recursion Pharmaceuticals - GlobeNewswire - Tue Jul 8, 7:00AM CDT ...

It's encouraging to think that multiple startups will find ways to leverage AI and other fields to accelerate drug discovery and improve patient outcome.

Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed after the company reported weaker-than-expected first-quarter 2025 ...

Recursion Pharmaceuticals , Inc. (NASDAQ:RXRX), currently trading at $5.11 after declining over 10% in the past week, announced the results of its 2025 annual meeting of stockholders held on ...